

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **May 7, 2014**

Tekmira Pharmaceuticals

(Exact name of registrant as specified in its charter)

British Columbia, Canada
(State or other jurisdiction
of incorporation)

001-34949
(Commission File Number)

980597776
(IRS Employer Identification No.)

**100-8900 Glenlyon Parkway
Burnaby, British Columbia
Canada**
(Address of principal executive offices)

V5J 5J8
(Zip Code)

Registrant's telephone number, including area code: **(604) 419-3200**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

INCORPORATION BY REFERENCE

This Form 8-K is hereby incorporated by reference as an exhibit to the registration statement on Form F-10 (File No. 333-194068) of Tekmira Pharmaceuticals Corporation.

Item 8.01. Other Events.

On May 7, 2014 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

<u>Exhibit</u>	<u>Description</u>
99.1	Press release dated May 7, 2014

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Tekmira Pharmaceuticals

(Registrant)

/s/ **BRUCE G. COUSINS**

May 7, 2014

(Date)

Bruce G. Cousins

Executive Vice President and Chief Financial Officer

Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter Financial Results

VANCOUVER, British Columbia, May 7, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it will hold a conference call and webcast on Wednesday, May 14, 2014 at 1:30 pm Pacific Time (4:30 pm Eastern Time) to provide a corporate update and report financial results for the first quarter ended March 31, 2014.

Conference Call and Webcast Information

A live webcast of the call can be accessed through the Investor section of Tekmira's website at www.tekmira.com. Or, alternatively, to access the conference call, please dial 914-495-8556 or 1-866-393-1607.

An archived webcast will be available on the Tekmira website approximately two hours after the event. Alternatively, you may access a replay of the conference call by calling 404-537-3406 or 1-855-859-2056 and referencing conference ID 41342533.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmira.com. Tekmira is based in Vancouver, B.C.

CONTACT: Investors

Bruce Cousins
Exec VP & CFO
Phone: 604-419-3200
Email: ir@tekmira.com

Media

Alan Bayless
Longview Communications Inc.
Phone: 604-694-6035
Email: abayless@longview.ca